Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Debunking Myths in the US Healthcare System
Your Article Summary
See Latest ArticlesVaccines for the Treatment of Non-Small Cell Lung Cancer: A Renewed Anticancer Strategy
The Oncologist, 09/25/09
Gridelli C et al. – Carcinoma of the lung is the leading cause of cancer death worldwide, with non–small cell lung cancer (NSCLC) constituting about 85% of all new diagnoses. Standard approaches for each NSCLC stage have reached a plateau in effectiveness. A variety of novel approaches are now being investigated to improve the outcome of this disease. This paper reviews the main clinical trials involving several different cancer vaccines employed in the treatment of early and advanced stage NSCLC, focusing on those in advanced stages of development.
Related Articles
Lung cancer: a biologically different disease in women?
Women's Health, 10/30/09
Relevance Score: 83%
HRQoL changes, mood disorders and satisfaction after treatment in an unselected population of patients with lung cancer
The Clinical Respiratory Journal, 11/13/09
Relevance Score: 82%
Image-Guided Radiofrequency Ablation of Lung Neoplasm in 100 Consecutive Patients by a Thoracic Surgical Service
Annals of Thoracic Surgery, 10/23/09
Relevance Score: 82%
Noninvasive detection of lung cancer by analysis of exhaled breath
BMC Cancer, 10/09/09
Relevance Score: 82%
CYP2E1 Rsa I/Pst I polymorphism is associated with lung cancer risk among Asians
Lung Cancer, 10/06/09
Relevance Score: 82%
Today in Vaccine/Immunotherapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
New England Journal of Medicine, 12/03/09
Patterns of Influenza Vaccination among Medical Students
Infection Control and Hospital Epidemiology, 12/03/09
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years : The Lancet
The Lancet - Early Online Publication, 12/03/09
Article Search
Sponsor